Clinical Trial: Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Chronic Lung Disease of Prematurity
Study Type: INTERVENTIONAL
Official Title: Phase 1 Safety Trial of Recombinant Surfactant Protein D to Prevent Neonatal Chronic Lung Disease
Brief Summary:
The purpose of this study is to identify the safest dose of recombinant surfactant protein D (drug name: rfhSP-D) that can be administered to preterm infants born at less than 28 weeks gestation, and to help identify whether this can prevent the development of neonatal chronic lung disease.
Read more